Microbot Medical's (MBOT) LIBERTY Endovascular Robotic System trial expands to Baptist Hospital of Miami, promising advancements in clinical outcomes and endovascular procedures.
Lucid Diagnostic's (LUCD) ESOGUARD BE-1 study data shows high sensitivity and negative predictive value for the EsoGuard test, enhancing early detection of esophageal precancer in a screening population.
DaVita's (DVA) strength in its kidney care segment raises optimism about the stock.